Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Virta Health

Two GLP-1 desks, one scoreboard. We put Sesame Care and Virta Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 405 · Grade C

Virta Health

Visit Virta Health Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 55 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Virta Health a bad call — it's best for readers who want plan members wanting nutrition-first care with optional monitored glp-1 use. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
40
Supply Reliability
92
77
Transparency
94
27
Access Breadth
84
36
Clinical Oversight
80
81
Track Record
92
80
Sesame CareBrief Score 87 · 55Virta Health

Price, coverage & the tracker

Sesame CareVirta Health
Brief Score87/100 (B+)55/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)Not disclosed
TirzepatideBrand Zepbound (price varies)Not disclosed
CoverageNationwide marketplaceCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Virta Health: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.